1. Home
  2. NOAH vs REPL Comparison

NOAH vs REPL Comparison

Compare NOAH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NOAH

Noah Holdings Limited

HOLD

Current Price

$10.18

Market Cap

653.4M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$2.67

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOAH
REPL
Founded
2005
2015
Country
China
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
653.4M
692.8M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
NOAH
REPL
Price
$10.18
$2.67
Analyst Decision
Hold
Hold
Analyst Count
2
9
Target Price
$11.00
$5.67
AVG Volume (30 Days)
149.9K
8.3M
Earning Date
05-27-2026
05-21-2026
Dividend Yield
5.68%
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.71
N/A
P/E Ratio
$13.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.13
$1.50
52 Week High
$12.84
$13.24

Technical Indicators

Market Signals
Indicator
NOAH
REPL
Relative Strength Index (RSI) 42.03 33.11
Support Level $9.64 $2.68
Resistance Level $10.72 $8.82
Average True Range (ATR) 0.27 0.74
MACD 0.07 -0.22
Stochastic Oscillator 33.89 16.33

Price Performance

Historical Comparison
NOAH
REPL

About NOAH Noah Holdings Limited

Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: